Survey on the prevalence and management of hypoparathyroidism in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather comprehensive data on the epidemiology, medication management, and complications associated with hypoparathyroidism specifically in France. Given the lack of published data on this condition in the country, the study will collect information from patients diagnosed with chronic hypoparathyroidism. The data will help to understand the prevalence and treatment patterns, as well as the complications that arise from this condition. The findings could inform better management strategies for patients suffering from hypoparathyroidism.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patient fro whom chronic hypoparathyroidism is diagnosed
* patient living in France

Exclusion Criteria:

* patient who does not want his data to be collected in this registry
* pseudo-hypoparathyroidism
* acute hypoparathyroidism

Where it's running

• Felix Guyon Hospital
  Saint-Denis, La Réunion, France Recruiting
• Hôpital Privé de Provence
  Aix-en-Provence, France Recruiting
• Amiens University Hospital
  Amiens, France Recruiting
• Clinic Auch Area
  Auch, France Recruiting
• Henri Mondor Hospital
  Aurillac, France Recruiting
• Jean Minjoz Hospital
  Besançon, France Recruiting

+7 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Jean-Philippe Bertocchio, MD, PhD — European Georges Pompidou Hospital, APHP
• Study coordinator: Jean-Philippe Bertocchio, MD, PhD
• Email: jpbertocchio@gmail.com
• Phone: 800-555-5555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• German Hypoparathyroidism Registry

  This registry in Germany collects information from adults with chronic hypoparathyroidism or pseudohypoparathyroidism to better understand how the condition affects people over time and to support future research.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857460

• Encaleret for Chronic Hypoparathyroidism: Testing if it helps symptoms and safety

  This study tests whether taking encaleret pills can help people with chronic hypoparathyroidism, while being safe and tolerable.

  Recruiting at 5 sites Phase 3 Calcilytix Therapeutics, Inc., a BridgeBio company · Reno, Nevada and 4 other locations · NCT07805356

• Palopegteriparatide in adolescents with long-term hypoparathyroidism

  This study tests whether a once-daily palopegteriparatide shot helps adolescents with long‑standing hypoparathyroidism and whether it’s safe for them.

  Recruiting at 3 sites Phase 3 Ascendis Pharma A/S · Bron and 2 other locations · NCT07706764

• Canvuparatide vs placebo in adults with hypoparathyroidism

  This study tests whether weekly canvuparatide can help adults with hypoparathyroidism feel better and keep calcium levels steady compared with a placebo.

  Recruiting at 22 sites Phase 3 MBX Biosciences · Englewood, Colorado and 21 other locations · NCT07699471

• NIRAF-guided identification of parathyroids during thyroidectomy

  A wearable near-infrared autofluorescence device is being tested to help surgeons find and protect the parathyroid glands during thyroid surgery in adults.

  Recruiting Ss. Cyril and Methodius University of Skopje · Skopje · NCT07617584

• Pregnancy registry tracking outcomes after YORVIPATH exposure during pregnancy and breastfeeding

  This registry collects information from pregnant or breastfeeding people with hypoparathyroidism who took YORVIPATH to see if the exposure affects pregnancy, the baby, or infant outcomes through the first year of life.

  Recruiting Ascendis Pharma A/S · Morgantown, West Virginia · NCT07345494

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.